ClinicalTrials.gg
RecruitingNCT06243640BGFN-2022-02Updated Feb 6, 2024

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

A Phase 3 interventional study of Buagafuran capsules, 15mg/ capsule and Buagafuran capsules mimic, 0mg/ capsule in Generalized Anxiety Disorder, sponsored by Beijing Union Pharmaceutical Factory Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Beijing Union Pharmaceutical Factory Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jul 2023, registered Jan 2024).
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Generalized Anxiety Disorder with a site in China — 16 open to participants now, 16 under way, 3 of them phase 3. Generalized Anxiety Disorder · China.

Planned enrollment
2nd of 20
504 · median 122
Started
2023
with 4 others
Phase 3
5 of 23
3 open now
Primary completion
2026-06
later than 4 of 15 live
Registered
10th of 23
by date
Lead sponsor
3 of 23
Beijing Union Pharmaceutical Factory Ltd

Among the 23 studies in Generalized Anxiety Disorder with a site in China, this one is the 2nd largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2023, is one of 5 in phase 3, reaches primary completion later than 4 of the 15 other live ones, and was the 10th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

16 of the 23 studies in Generalized Anxiety Disorder with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Generalized Anxiety Disorder with a site in China, or all of them as a file.
02

Study summary

A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD

Read the detailed description

This was a multi-center, randomized, double-blind, placebo-controlled, fixed-dose phase III clinical trial. Hierarchical factors for whether new generalized anxiety disorder (GAD) (new GAD vs. Non-new GAD).

Qualified subjects, according to the ratio of 1:1:1, were randomized into high-dose group, low-dose group and placebo-control group, and received a treatment course of 8 weeks. Participants were followed from baseline outpatient visit until end of the follow-up period( 10 weeks and 7 visits in total).

03

Conditions studied

  • Generalized Anxiety Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatients aged 18-65 years old, of both sexes;
  2. Met the , 5th Edition (DSM-5) criteria for generalized anxiety disorder (GAD) and confirmed by the Brief International Neuropsychiatric Interview (M.I.N.I.);
  3. The patient requires psychiatric medication;
  4. Hamilton Anxiety Scale (HAMA) score ≥20, Hamilton Depression Scale (HAMD-17) score ≤2, Clinical Global Impression Scale (CGI-S) score ≥4 at screening and baseline Points;
  5. Able to understand and voluntarily participate in this trial, signed .

Exclusion criteria

Exclusion Criteria:

  1. Patients with serious suicide risk at present, or HAMD-17 item 3-suicide score ≥3;
  2. Patients with HAMD-17 > 17;
  3. Patients whose HAMA scores decreased by ≥20% in the baseline period compared with the screening period:
  4. Those who met the diagnostic criteria for other mental disorders except GAD;
  5. Patients with previous history of depression, obsessive-compulsive disorder, bipolar disorder, psychotic disorder, factitious disorder and somatoform disorder; There were severe personality disorders, especially antisocial, borderline, or histrionic personality disorder, which were judged by the investigator to affect the patient's adherence to the study protocol;
  6. Alcohol or drug abuse or dependence within 180 days before screening;
  7. With severe or unstable has clinical significance of somatic disease, including any cardiovascular, cancer, kidney, respiratory, endocrine (including abnormal thyroid function), digestion, blood (such as with bleeding tendency) or nervous system diseases;
  8. Patients whose physical examination or vital signs were abnormal and (e.g. inadequately controlled hypertension, systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);
  9. Patients with a history of epilepsy or any other disease that may induce seizures, except convulsions caused by febrile convulsions in children;
  10. Important abnormalities in laboratory tests during the screening period, such as abnormal liver function tests ( or aspartate transaminase > 2 times the normal value); Renal insufficiency (blood urea nitrogen or creatinine > 1.2 times the );
  11. Clinically significant abnormalities on electrocardiography ( corrected by Fridericia method: ≥450 ms for men or ≥470 ms for women) or conditions deemed ineligible by the investigators;
  12. Patients who had undergone psychiatric surgery, electroconvulsive therapy or transcranial magnetic stimulation within 90 days before screening;
  13. Patients treated with β-blockers within 90 days before screening;
  14. Patients with severe , or allergic to at least 2 kinds of drugs (including photosensitivity);
  15. Patients who had previously used two or more antidepressants and/or benzodiazepines at a clinically appropriate dose for at least 4 weeks but were still ineffective;
  16. Receiving systemic psychotherapy or other non-pharmacological treatments (e.g., acupuncture, hypnosis, or phototherapy) within 6 weeks before the baseline visit;
  17. Those who had used benzodiazepines within -7 to -1 days before screening, such as lorazepam, oxazepam, and alprazolam for less than 5 half-lives; The use of benzodiazepines with longer half-lives, such as diazepam, clonazepam, nitrazepam, estazolam, and flurazepam, not more than 5 half-lives or less than 30 days from the screening period, or the use of barbiturates not more than 5 half-lives or less than 30 days from the screening period;
  18. Patients treated with monoamine oxidase inhibitors within -7 to 1 day before screening; Patients treated with fluoxetine within 30 days before screening;
  19. Patients using antipsychotics, antidepressants and mood stabilizers with less than 5 half-lives before the baseline ;
  20. Patients who discontinued traditional Chinese medicine, melatonin, and St. John's wort for less than 3 days before the baseline visit;
  21. In the experimental drug delivery within 7 days before and during the test, cannot fast grapefruit or grapefruit juice;
  22. Women during pregnancy or lactation experiments have fertility requirement (including men), and not to the male, the female patients is safe and effective measures;
  23. Unable to take medicine as prescribed;
  24. Participants enrolled in other clinical trials within 90 days before screening;
  25. Patients with other conditions deemed by the investigator to be ineligible for enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
504 participants (estimated)

Study arms

  • Experimental
    High-dose experimental group

    Subjects took 120mg per day of Buagafuran capsules after breakfast and dinner for 8 weeks

    Drug: Buagafuran capsules, 15mg/ capsule

  • Experimental
    Low-dose experimental group

    Subjects took 60mg per day of Buagafuran capsules and Buagafuran capsules mimic after breakfast and dinner for 8 weeks

    Drug: Buagafuran capsules, 15mg/ capsule · Drug: Buagafuran capsules mimic, 0mg/ capsule

  • Placebo comparator
    Placebo-Control group

    Subjects took 0 mg per day Buagafuran capsules mimic after breakfast and dinner for 8 weeks

    Drug: Buagafuran capsules mimic, 0mg/ capsule

Interventions

  • DrugBuagafuran capsules, 15mg/ capsule

    Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;

  • DrugBuagafuran capsules mimic, 0mg/ capsule

    Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;

06

What researchers measure

Primary outcomes

  1. Change in Hamilton anxiety scale score after treatment

    The Hamilton Anxiety (HAMA) Scale total score reflects the severity of the patients anxiety symptoms. The primary efficacy end point was the change from baseline to week 8 in HAMA total score to determine the superiority of buagafuran capsules over placebo. The larger the difference between buagafuran capsules over placebo, the better the curative effect.

    Time frame: the end of week 8

Secondary outcomes

  1. Change in each factor score and item score of Hamilton anxiety scale

    One of the secondary efficacy end point was the change from baseline to week 4 and 8 in each factor score and item score of Hamilton anxiety scale to determine the superiority of buagafuran capsules over placebo. The larger the difference between buagafuran capsules over placebo, the better the curative effect.

    Time frame: the end of week 4 and 8

  2. Clinical global impression of improvement score

    Subjective improvement of buagafuran capsules will be assessed using Clinical Global Impression of Improvement (CGI-I) score at week 4 and 8. The larger the difference between buagafuran capsules over placebo, the better the curative effect.

    Time frame: the end of week 4 and 8

  3. Clinical global impression of severity score

    Subjective severity of buagafuran capsules will be assessed by the change from baseline to week 4 and 8 with Clinical global impression of severity (CGI-S) score, to determine the superiority of buagafuran capsules over placebo. The larger the difference between buagafuran capsules over placebo, the better the curative effect.

    Time frame: the end of week 4 and 8

  4. Complete remission rate

    Complete remission rate was the proportion of subjects with HAMA total scale score ≤7 at the end of week 8. The larger the difference between buagafuran capsules over placebo, the better the curative effect.

    Time frame: the end of week 8

  5. Response rate

    Response rate was the proportion of subjects with HAMA total score decreased by ≥50% from baseline to week 8. The larger the difference between buagafuran capsules over placebo, the better the curative effect.

    Time frame: the end of week 8

  6. Rapid-onset rate

    Rapid-onset rate was the proportion of subjects with HAMA total score decreased by ≥20% from baseline to week 1 and 2. The larger the difference between buagafuran capsules over placebo, the better the curative effect.

    Time frame: the end of week 1 and 2

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jun 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2024
First posted
Feb 6, 2024
StartActual
Jul 25, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06243640
Lead sponsor
Beijing Union Pharmaceutical Factory Ltd
Collaborators
R&G Pharma Studies Co.,Ltd.
Responsible party
Sponsor
First posted
Feb 6, 2024
Start date
Jul 25, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 6, 2024

Study contacts

Tao Sun
Contact
sunny.suntao@aliyun.com
13621169498

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion